HR+ Advanced or Metastatic Breast Cancer Clinical Trial
Official title:
Managed Access Program (MAP) to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer Resistant or Refractory to Available Treatment Options
The purpose of this Cohort Treatment Plan is to allow access to alpelisib for eligible patients diagnosed with hormone receptor positive, advanced or metastatic breast cancer harboring a phosphatidylinositol 3-kinase (PI3K)CA mutation. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.
n/a